Amyloid Pathology Induces Dysfunction of Systemic Neurotransmission in Aged APPswe/PS2 Mice

Overview

Journal Front Neurosci

Date 2022 Aug 22

PMID 35992913

Authors

Se Jong Oh

Namhun Lee

Kyung Rok Nam

Kyung Jun Kang

Sang Jin Han

Kyo Chul Lee

Yong Jin Lee

Jae Yong Choi

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate how amyloid pathology affects the functional aspects of neurotransmitter systems in Alzheimer's disease. APPswe/PS2 mice (21 months of age) and wild-type (WT) mice underwent positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). First, we obtained F-FDG and F-florbetaben PET scans to evaluate neuronal integrity and amyloid pathology. Second, F-FPEB and F-FMZ PET data were acquired to assess the excitatory-inhibitory neurotransmission. Third, to monitor the dopamine system, F-fallypride PET was performed. Amyloid PET imaging revealed that radioactivity was higher in the AD group than that in the WT group, which was validated by immunohistochemistry. In the cortical and limbic areas, the AD group showed a 25-27% decrease and 14-35% increase in the glutamatergic and GABAergic systems, respectively. The dopaminergic system in the AD group exhibited a 29% decrease in brain uptake compared with that in the WT group. A reduction in glutamate, -acetylaspartate, and taurine levels was observed in the AD group using MRS. Our results suggest that dysfunction of the neurotransmitter system is associated with AD pathology. Among the systems, the GABAergic system was prominent, implying that the inhibitory neurotransmission system may be the most vulnerable to AD pathology.

Citing Articles

[F]Flotaza for Aβ Plaque Diagnostic Imaging: Evaluation in Postmortem Human Alzheimer's Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice.

Sandhu Y, Bath H, Shergill J, Liang C, Syed A, Ngo A Int J Mol Sci. 2024; 25(14).

PMID: 39063132 PMC: 11277463. DOI: 10.3390/ijms25147890.

References

Snellman A, Lopez-Picon F, Rokka J, Salmona M, Forloni G, Scheinin M . Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med. 2013; 54(8):1434-41. DOI: 10.2967/jnumed.112.110163. View

Rowley P, Samsonov A, Betthauser T, Pirasteh A, Johnson S, Eisenmenger L . Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. Semin Ultrasound CT MR. 2020; 41(6):572-583. DOI: 10.1053/j.sult.2020.08.011. View

Kemppainen N, Laine M, Laakso M, Kaasinen V, Nagren K, Vahlberg T . Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci. 2003; 18(1):149-54. DOI: 10.1046/j.1460-9568.2003.02716.x. View

Dixon R, Bradley K, Budge M, Styles P, Smith A . Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002; 125(Pt 10):2332-41. DOI: 10.1093/brain/awf226. View

Margolis E, Lock H, Hjelmstad G, Fields H . The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons?. J Physiol. 2006; 577(Pt 3):907-24. PMC: 1890372. DOI: 10.1113/jphysiol.2006.117069. View

Swanson L . The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull. 1982; 9(1-6):321-53. DOI: 10.1016/0361-9230(82)90145-9. View

Um J, Kaufman A, Kostylev M, Heiss J, Stagi M, Takahashi H . Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron. 2013; 79(5):887-902. PMC: 3768018. DOI: 10.1016/j.neuron.2013.06.036. View

Richards J, Higgins G, Ouagazzal A, Ozmen L, Kew J, Bohrmann B . PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003; 23(26):8989-9003. PMC: 6740398. View

Luo F, Rustay N, Ebert U, Hradil V, Cole T, Llano D . Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging. 2010; 33(5):933-44. DOI: 10.1016/j.neurobiolaging.2010.08.005. View

10.

Barnard E, Skolnick P, Olsen R, Mohler H, Sieghart W, Biggio G . International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998; 50(2):291-313. View

11.

Srinivasan S, Crandall J, Gajwani P, Sgouros G, Mena E, Lodge M . Human Radiation Dosimetry for Orally and Intravenously Administered F-FDG. J Nucl Med. 2019; 61(4):613-619. PMC: 9374043. DOI: 10.2967/jnumed.119.233288. View

12.

Moon B, Park J, Lee H, Kim J, Kil H, Lee B . Highly efficient production of [(18)F]fallypride using small amounts of base concentration. Appl Radiat Isot. 2010; 68(12):2279-84. DOI: 10.1016/j.apradiso.2010.06.016. View

13.

Mosconi L . Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging. 2014; 1(4). PMC: 3881550. DOI: 10.1007/s40336-013-0026-y. View

14.

Poisnel G, Herard A, El Tannir El Tayara N, Bourrin E, Volk A, Kober F . Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging. 2011; 33(9):1995-2005. PMC: 3666917. DOI: 10.1016/j.neurobiolaging.2011.09.026. View

15.

Ford T, Crewther D . A Comprehensive Review of the (1)H-MRS Metabolite Spectrum in Autism Spectrum Disorder. Front Mol Neurosci. 2016; 9:14. PMC: 4783404. DOI: 10.3389/fnmol.2016.00014. View

16.

Palner M, Beinat C, Banister S, Zanderigo F, Park J, Shen B . Effects of common anesthetic agents on [F]flumazenil binding to the GABA receptor. EJNMMI Res. 2016; 6(1):80. PMC: 5101239. DOI: 10.1186/s13550-016-0235-2. View

17.

Kulak A, Duarte J, Do K, Gruetter R . Neurochemical profile of the developing mouse cortex determined by in vivo 1H NMR spectroscopy at 14.1 T and the effect of recurrent anaesthesia. J Neurochem. 2010; 115(6):1466-77. DOI: 10.1111/j.1471-4159.2010.07051.x. View

18.

Costantini L, Barr L, Vogel J, Henderson S . Hypometabolism as a therapeutic target in Alzheimer's disease. BMC Neurosci. 2008; 9 Suppl 2:S16. PMC: 2604900. DOI: 10.1186/1471-2202-9-S2-S16. View

19.

Sabri O, Seibyl J, Rowe C, Barthel H . Beta-amyloid imaging with florbetaben. Clin Transl Imaging. 2015; 3(1):13-26. PMC: 4339690. DOI: 10.1007/s40336-015-0102-6. View

20.

Serrano-Pozo A, Frosch M, Masliah E, Hyman B . Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2012; 1(1):a006189. PMC: 3234452. DOI: 10.1101/cshperspect.a006189. View